Abbott Laboratories
ABT · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $41,950,000 | $40,109,000 | $43,653,000 | $43,075,000 |
| % Growth | 4.6% | -8.1% | 1.3% | – |
| Cost of Goods Sold | $20,625,000 | $20,072,000 | $21,330,000 | $19,861,000 |
| Gross Profit | $21,325,000 | $20,037,000 | $22,323,000 | $23,214,000 |
| % Margin | 50.8% | 50% | 51.1% | 53.9% |
| R&D Expenses | $2,823,000 | $2,719,000 | $2,852,000 | $2,738,000 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $11,651,000 | $10,883,000 | $11,109,000 | $11,276,000 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $14,474,000 | $13,602,000 | $13,961,000 | $14,014,000 |
| Operating Income | $6,825,000 | $6,435,000 | $8,362,000 | $9,200,000 |
| % Margin | 16.3% | 16% | 19.2% | 21.4% |
| Other Income/Exp. Net | $188,000 | $229,000 | -$56,000 | -$989,000 |
| Pre-Tax Income | $7,013,000 | $6,664,000 | $8,306,000 | $8,211,000 |
| Tax Expense | -$6,389,000 | $941,000 | $1,373,000 | $1,140,000 |
| Net Income | $13,402,000 | $5,723,000 | $6,933,000 | $7,071,000 |
| % Margin | 31.9% | 14.3% | 15.9% | 16.4% |
| EPS | 7.67 | 3.3 | 3.94 | 3.97 |
| % Growth | 132.4% | -16.2% | -0.8% | – |
| EPS Diluted | 7.64 | 3.27 | 3.91 | 3.94 |
| Weighted Avg Shares Out | 1,731,698 | 1,734,076 | 1,753,000 | 1,775,000 |
| Weighted Avg Shares Out Dil | 1,748,000 | 1,749,000 | 1,764,000 | 1,789,000 |
| Supplemental Information | – | – | – | – |
| Interest Income | $344,000 | $385,000 | $183,000 | $43,000 |
| Interest Expense | $603,000 | $698,000 | $315,000 | $410,000 |
| Depreciation & Amortization | $3,218,000 | $3,243,000 | $3,267,000 | $3,538,000 |
| EBITDA | $10,834,000 | $10,605,000 | $11,888,000 | $12,159,000 |
| % Margin | 25.8% | 26.4% | 27.2% | 28.2% |